Boston Scientific Corporation (BSX) with a market cap of $144.2 billion, develops and markets medical devices worldwide. It is set to announce Q3 2025 earnings with analysts expecting an adjusted EPS of $0.71, a 12.7% increase from the previous year. For fiscal 2025, analysts predict an adjusted EPS of $2.98, up 18.7%.

BSX shares have risen 14.5% in the past year, outperforming the Health Care Select Sector but lagging behind the S&P 500. After reporting better-than-expected Q2 2025 results, including revenue of $5.1 billion, BSX saw a 4.5% jump in its stock. Strong demand for key cardiovascular devices boosted investor confidence.

Analysts are bullish on BSX stock, with a consensus “Strong Buy” rating. Of 32 analysts, 27 recommend a “Strong Buy,” three suggest a “Moderate Buy,” and two have a “Hold” rating. The average analyst price target for Boston Scientific is $126.16, indicating a potential upside of 30.5%.

Read more at Yahoo Finance: What You Need To Know Ahead of Boston Scientific’s Earnings Release